Table 1 |
||||
|
Reported efficacy of rituximab in nonrandomised trials of systemic lupus erythematosus |
||||
|
Study |
Rituximab regimen |
Organ-specific disease |
Number of patients/follow-up (months) |
Method of assessment (mean disease activity score before/after B-cell depletion) |
|
|
||||
|
Variable |
No (7 LN) |
17/12 |
SLAM improved in patients achieving effective B-cell depletion (6.8/5.2) |
|
|
Leandro and colleagues [15]b |
2-dose |
No (17/19 LN) |
19/6 |
BILAG (13.9/5) |
|
Vigna-Perez and colleagues [65] |
2-dose |
Yes, LN |
22/3 |
Mexico-SLEDAI (10.8/6.8) |
|
Cambridge and colleagues [21]b |
2-dose |
No (12/15 LN) |
15/6 |
BILAG |
|
Tamimoto and colleagues [66] |
Variable |
No (4/8LN) |
8 |
SLEDAI (17.6/7.3) |
|
Tokunaga and colleagues [28] |
Variable |
Yes, NPSLE |
10/7 to 45 |
Neurological parameters (GCS) |
|
Tanaka and colleagues [67] |
2-dose |
No (6LN) |
14/7 |
BILAG (12.5/7.1) |
|
Ng and colleagues [17]b |
2-dose |
No (21 LN) |
32/39 |
BILAG (13/5) |
|
Reynolds and colleagues [45] |
Variable |
No |
11/10 |
BILAG (median reduction of 7.5) |
|
Li and colleagues [68], |
2-dose |
Yes, LN |
19/12 |
SLEDAI (9.2/2.5) |
|
Lu and colleagues [69]b |
2-dose |
No (33/45 LN) |
45/39.6 |
BILAG (12/5) |
|
Pepper and colleagues [56] |
2-dose + MMF maintenance |
Yes, LN |
20/12 |
Renal parameters improved in 14/18 at 12 months |
|
Catapano and colleagues [19] |
4-dose (15) or2-dose + CYC (16) |
No (11 LN) |
31/30 |
BILAG (14.5/3.5 at 24 months) |
|
Sfikakis and colleagues [70] |
4-dose |
Yes, LN |
10/12 |
Renal parameters |
|
Gottenberg and colleagues [71] |
4-dose |
No (4 LN) |
13/8.3 |
SLEDAI (8/2) |
|
Smith and colleagues [18] |
4-dose, retreated with 2-dose |
No |
11/24 |
BILAG (14/2) |
|
Gunnarsson and colleagues [72] |
4-dose |
Yes, LN |
7/6 |
SLEDAI (15/3) |
|
Galarza and colleagues [73] |
4-dose |
No |
43/12 |
SLEDAI (12.5/4.5) |
|
Jonsdottir and colleagues [74] |
4-dose |
No (10 LN) |
16/27 |
SLEDAI (12.1/4.7) |
|
Lindholm and colleagues [75] |
4-dose |
No (17 LN) |
29/22 |
Renal parameters |
|
Sutter and colleagues [76] |
4-dose |
No |
12 |
SLEDAI (9/5) |
|
Boletis and colleagues [77] |
4-dose |
Yes, LN |
10/38 |
Renal parameters |
|
Melander and colleagues [78] |
4-dose regimen (10 retreated) |
Yes, LN |
20/22 |
12/20 improved |
|
|
||||
|
BILAG, British Isles Lupus Assessment Group; CYC, cyclophosphamide; GCS, Glasgow Coma Scale; MMF, mycophenolate mofetil; SLAM, systemic lupus activity measure; LN, lupus nephritis; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. aRandomised controlled trial. bSame cohort in these studies. |
||||
|
Reddy et al. Arthritis Research & Therapy 2013 15(Suppl 1):S2 doi:10.1186/ar3910 |
||||